Related Experiment Video
Updated: Jun 11, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Antiangiogenic and antitumor effects of Trypanosoma cruzi Calreticulin
Nandy C López1, Carolina Valck, Galia Ramírez
1Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Background:
In Latin America, 18 million people are infected with Trypanosoma cruzi, the agent of Chagas' disease, with the greatest economic burden. Vertebrate calreticulins (CRT) are multifunctional, intra- and extracellular proteins. In the endoplasmic reticulum (ER) they bind calcium and act as chaperones. Since human CRT (HuCRT) is antiangiogenic and suppresses tumor growth, the presence of these functions in the parasite orthologue may have consequences in the host/parasite interaction. Previously, we have cloned and expressed T. cruzi calreticulin (TcCRT) and shown that TcCRT, translocated from the ER to the area of trypomastigote flagellum emergence, promotes infectivity, inactivates the complement system and inhibits angiogenesis in the chorioallantoid chicken egg membrane. Most likely, derived from these properties, TcCRT displays in vivo inhibitory effects against an experimental mammary tumor.
Methodology And Principal Findings:
TcCRT (or its N-terminal vasostatin-like domain, N-TcCRT) a) Abrogates capillary growth in the ex vivo rat aortic ring assay, b) Inhibits capillary morphogenesis in a human umbilical vein endothelial cell (HUVEC) assay, c) Inhibits migration and proliferation of HUVECs and the human endothelial cell line Eahy926. In these assays TcCRT was more effective, in molar terms, than HuCRT: d) In confocal microscopy, live HUVECs and EAhy926 cells, are recognized by FITC-TcCRT, followed by its internalization and accumulation around the host cell nuclei, a phenomenon that is abrogated by Fucoidin, a specific scavenger receptor ligand and, e) Inhibits in vivo the growth of the murine mammary TA3 MTXR tumor cell line.
Conclusions/Significance:
We describe herein antiangiogenic and antitumor properties of a parasite chaperone molecule, specifically TcCRT. Perhaps, by virtue of its capacity to inhibit angiogenesis (and the complement system), TcCRT is anti-inflammatory, thus impairing the antiparasite immune response. The TcCRT antiangiogenic effect could also explain, at least partially, the in vivo antitumor effects reported herein and the reports proposing antitumor properties for T. cruzi infection.
Insights
Trypanosoma cruzi calreticulin (TcCRT) exhibits anti-angiogenic and anti-tumor properties, inhibiting both capillary growth and tumor development. This parasite chaperone molecule shows potential for therapeutic applications against cancer and Chagas
Area of Science:
- Parasitology
- Molecular Biology
- Oncology
Background:
- Chagas' disease, caused by Trypanosoma cruzi, affects 18 million people in Latin America.
- Calreticulins (CRT) are multifunctional proteins involved in calcium binding and protein folding.
- Human CRT (HuCRT) exhibits anti-angiogenic and tumor-suppressive functions.
Purpose of the Study:
- To investigate the anti-angiogenic and anti-tumor properties of T. cruzi calreticulin (TcCRT).
- To compare the efficacy of TcCRT with human CRT (HuCRT).
- To explore the potential therapeutic implications of TcCRT.
Main Methods:
- Ex vivo rat aortic ring assay for capillary growth inhibition.
- In vitro assays using human umbilical vein endothelial cells (HUVECs) and Eahy926 cell line for capillary morphogenesis, migration, and proliferation.
- Confocal microscopy to track TcCRT internalization by endothelial cells.
- In vivo studies using a murine mammary tumor model.
Main Results:
- TcCRT, particularly its N-terminal domain (N-TcCRT), abrogated capillary growth and inhibited endothelial cell functions.
- TcCRT demonstrated greater efficacy than HuCRT in inhibiting angiogenesis.
- TcCRT was internalized by endothelial cells, with uptake mediated by scavenger receptors.
- TcCRT significantly inhibited the growth of a murine mammary tumor cell line in vivo.
Conclusions:
- TcCRT possesses significant anti-angiogenic and anti-tumor properties.
- TcCRT's anti-angiogenic capacity may contribute to its anti-tumor effects and potentially impair anti-parasite immune responses.
- TcCRT represents a potential therapeutic candidate for cancer treatment and warrants further investigation.
More Related Videos
Related Concept Videos
American Trypanosomiasis
Antiprotozoal Agents

